Study results from University of Massachusetts, Memorial Cancer Center broaden understanding of colon cancer risk factors
2007 NOV 19 -- Current study results from the report, 'p66 Shc tumor levels show a strong prognostic correlation with disease outcome in stage IIA colon cancer,' have been published. According to recent research published in the journal Clinical Cancer Research, "Most stage IIA colon cancer patients receive no adjuvant therapy despite an estimated 15% risk of disease-related death within 5 years of resection. Prognostication of disease outcome would benefit the clinician by categorizing patients with stage IIA disease by risk." "The abundance of the signal transduction proteins p66 Shc and tyrosine-phosphorylated (PY)-Shc in tumor cells is a prognostic indicator of disease outcome in breast cancer, suggesting that Shc analysis may provide prognostic information in stage IIA colon cancer Immunohistochemical staining of p66 Shc and PY-Shc was examined in resection specimens from 240 chemotherapy-naïve patients with stage IIA (T(3)N(0)M(0)) colon cancer from two independent (130 and 110 cases, respectively) retrospective cohorts. Staining was scored on a 0 to 5 scale and correlated with relapse-free survival and disease-specific survival in a multivariate analysis to obtain hazard ratios (HR) for both outcomes In a pooled analysis of both cohorts, p66 Shc score was a significant prognostic indicator of relapse-free survival (full-range HR, 13.0; p=0.012) and disease-specific survival (full-range HR, 36.6; p=0.004) when analyzed as a continuous variable in a multivariate Cox proportional hazards model stratified by study site and adjusted for age, sex, grade, and lymphovascular involvement," wrote S.R. Grossman and colleagues, University of Massachusetts, Memorial Cancer Center. The researchers concluded: "PY-Shc in this multivariate Cox model, however, did not achieve statistical significance for either outcome Measuring p66 Shc tumor levels provides a unique and simple tool for stratifying stage IIA colon cancer patients by risk of recurrence and disease-specific death and may assist in determining treatment strategies for these patients." Grossman and colleagues published their study in Clinical Cancer Research (p66 Shc tumor levels show a strong prognostic correlation with disease outcome in stage IIA colon cancer. Clinical Cancer Research, 2007;13(19):5798-804). For additional information, contact S.R. Grossman, University of Massachusetts Memorial Cancer Center, Dept. of Cancer Biology, MA USA.. The publisher's contact information for the journal Clinical Cancer Research is: American Association Cancer Research, 615 Chestnut St., 17TH Floor, Philadelphia, PA 19106-4404, USA. Keywords: United States, Colon Cancer Risk Factors, Cancer Research, Colon Cancer, Colon Carcinoma, Oncology, Therapy, Treatment. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
